Targeting a protein complex to treat therapy-resistant prostate cancer
Modulating HSP70/STUB1 machinery in therapy-resistant prostate cancer
This study is looking at how to help men with advanced prostate cancer that doesn't respond to usual treatments by using a common medication to target a specific protein, which could make their current therapies work better again.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-10927315 on NIH RePORTER |
What this research studies
This research investigates how to overcome resistance to anti-androgen therapies in prostate cancer, particularly in cases where the cancer has evolved to a more aggressive form known as castrate-resistant prostate cancer (CRPC). The approach focuses on modulating the HSP70/STUB1 protein complex, which plays a crucial role in maintaining the stability of androgen receptors that drive cancer growth. By using an FDA-approved drug called niclosamide, the researchers aim to reduce the levels of a variant androgen receptor that contributes to treatment resistance, potentially restoring the effectiveness of existing therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with castrate-resistant prostate cancer who have developed resistance to standard anti-androgen treatments.
Not a fit: Patients with early-stage prostate cancer or those who have not yet undergone anti-androgen therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for men with therapy-resistant prostate cancer, enhancing their chances of survival.
How similar studies have performed: Previous research has shown promise in targeting similar protein complexes to overcome drug resistance in cancer, indicating a potential for success with this approach.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Liu, Chengfei — University of California at Davis
- Study coordinator: Liu, Chengfei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.